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Abstract
Background: Exported proteases are commonly associated with virulence in bacterial pathogens,
yet there is a paucity of information regarding their role in Mycobacterium tuberculosis. There are
five genes (mycP1-5) present within the genome of Mycobacterium tuberculosis H37Rv that encode
a family of secreted, subtilisin-like serine proteases (the mycosins). The gene mycP1 (encoding
mycosin-1) was found to be situated 3700 bp (four ORF's) from the RD1 deletion region in the
genome of the attenuated vaccine strain M. bovis BCG (bacille de Calmette et Guérin) and was
selected for further analyses due to the absence of expression in this organism.
Results: Full-length, 50 kDa mycosin-1 was observed in M. tuberculosis cellular lysates, whereas
lower-molecular-weight species were detected in culture filtrates. A similar lower-molecular-
weight species was also observed during growth in macrophages. Mycosin-1 was localized to the
membrane and cell wall fractions in M. tuberculosis by Western blotting, and to the cell envelope by
electron microscopy. Furthermore, M. tuberculosis culture filtrates were shown to contain a
proteolytic activity inhibited by mixed serine/cysteine protease inhibitors and activated by Ca2+,
features typical of the subtilisins.
Conclusions: Mycosin-1 is an extracellular protein that is membrane- and cell wall-associated, and
is shed into the culture supernatant. The protein is expressed after infection of macrophages and
is subjected to proteolytic processing. Although proteolytically active mycosin-1 could not be
generated recombinantly, serine protease activity containing features typical of the subtilisins was
detected in M. tuberculosis culture filtrates.
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Microbial pathogens frequently utilize extracellular pro-
teases as virulence factors, which often contribute signifi-
cantly to pathology [1]. These proteases participate in
tissue destruction, inactivation of host defense molecules,
activation of key regulatory proteins or peptides, nutrient
acquisition and the processing of secreted signaling mole-
cules that regulate gene expression. The M. tuberculosis ge-
nome revealed the presence of a large number and variety
of putative protease genes, some encoding potential se-
creted proteases [2]. This includes a family of five subtili-
sin-like serine proteases, the mycosins (1–5), which share
a high degree of similarity and are constitutively expressed
in M. tuberculosis H37Rv [3]. In contrast to mycosin-2 and
-3, mycosin-1 is not expressed in the attenuated M. bovis
strain BCG, although the gene for mycosin-1 (mycP1) is
present in the genome of this organism. This gene was
found to be situated 3700 bp (four ORF's) from the RD1
deletion region, which has attracted considerable atten-
tion recently because of possibly being a locus of potential
diagnostic proteins. Therefore, mycosin-1 was selected for
further analysis. Here we report the cloning and expres-
sion of the gene for mycosin-1, mycP1, and the localiza-
tion of the native and recombinantly expressed mycosin-
1 protein to the bacterial cell wall / envelope. We show
that mycosin-1 could be detected in M. tuberculosis culture
filtrates and that these filtrates possess protease activity
that could partly be attributed to a serine protease, possi-
bly a subtilisin. Furthermore, we have demonstrated the
expression of mycosin-1 during growth in macrophages
and provide preliminary evidence that mycosin-1 may be
proteolytically processed intracellularly.
Results and discussion
Expression of mycosin-1 in E. coli (GST-fusion protein) and 
M. smegmatis and production of anti-mycosin-1 antiserum
A 73 kDa GST-mycosin-1 fusion protein was detected in
the insoluble (cell lysate) fraction of E. coli transformed
with pGEX-P1 (Fig. 1). Most of the GST-mycosin-1 fusion
protein was insoluble and significant amounts were lost
during purification, consistent with the high degree of hy-
drophobicity predicted from the amino acid sequence
(see Fig. 2). Addition of detergents to solubilize the fusion
protein increased the amount of GST-mycosin-1 in the
soluble fraction and enhanced purification yields. The pu-
rified product was used to generate antiserum against my-
cosin-1.
As reported previously [3], the purified anti-mycosin-1
antiserum was tested by performing Western blot analyses
on cellular lysates of M. smegmatis heterologously express-
ing mycosin-1. A ~50 kDa immunoreactive band was only
detected in M. smegmatis transformed with p19K-P1 (des-
ignated M. smegmatis -P1; Fig. 3, lanes 1–3), consistent
Figure 1
Expression of GST-mycosin-1 fusion protein in E. coli. Bacteria were transformed with vector only (pGEX-2T, left
panel) or vector expressing GST-mycosin-1 fusion protein (pGEX-P1, right panel). Lysates were prepared before (U) and after
(I) induction with 0.1 mM IPTG for 2 hours; recombinant proteins were purified (P) by GST-affinity chromatography. In each
case, fractions were resolved by SDS-PAGE (a) and then analyzed by Western blotting (b) using an anti-GST monoclonal anti-
body as the primary antibody. Molecular weights (in kDa) are indicated on the left.
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lated molecular mass of 46 kDa. The detection of the full-
length isoform suggests that propeptide cleavage did not
occur during expression in M. smegmatis.
Detection of mycosin-1 in M. tuberculosis cultures and 
during infection of macrophages
To examine expression of mycosin-1 in M. tuberculosis
GSH-3052, cellular proteins were extracted with SDS from
1-, 2-, 3-, 4- and 6-week cultures. A single immunoreactive
band of the same molecular weight as the recombinant
protein expressed in M. smegmatis-P1 was detected by
Western blot analysis using anti-mycosin-1 antiserum
Figure 2
Sequence analysis of the protein sequence of mycosin-1. (A) Sequence alignment of mycosin-1 with the B. amyloliquifa-
ciens subtilisin BPN protein. The conserved amino acid residues are indicated in bold. The catalytic residues (D-90, H-131, and
S-332, mycosin-1 numbering) are in open boxes; the oxyanion hole (N-237) is in a closed box. The mycosin-1 signal peptide
cleavage site (A-21/I-22) is shaded. The arrows below the BPN sequence bracket the propeptide sequence; arrows above
mycosin-1 indicate the predicted propeptide. Overlines (numbered 1–5) above the mycosin-1 sequence indicate hydrophobic
regions and correspond to domains 1–5 shown in (B). (B) Hydrophobicity plot of mycosin-1.
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growth curve of M. tuberculosis, but the highest expression
levels in cell lysates were detected in 1-week cultures [3].
Culture filtrates throughout the growth cycle also con-
tained mycosin-1 immunoreactivity, but a decrease in
molecular weight of mycosin-1 in the filtrates of weeks 2–
4 (results not shown) and a further decrease in the 6-week
culture (~40 kDa) (Fig. 3, lane 5), were observed. This sug-
gests that there may be processing of the mycosin-1
proenzyme at the later time points. Alternatively, it is also
possible that after extended culture, additional members
of the mycosin family of proteins are expressed that cross-
react with the anti-mycosin-1 antiserum, although no
cross-reactivity was observed previously with mycosin-2
and -3 [3]. In contrast, no mycosin-1 immunoreactivity
was detected in M. bovis BCG cell lysates or in M. smegma-
tis-P1 culture filtrates [3].
We next examined whether mycosin-1 is expressed during
infection of macrophages, by examining total cell lysates
of P388D1 macrophages infected with the M. tuberculosis
clinical strain GSH-3052. An immunoreactive band of
~40 kDa was detected by Western blotting in infected but
not uninfected cell lysates (Fig. 3, lanes 6 and 7). This
band was notably smaller than the ~50 kDa band ob-
served in cell lysates from broth-grown M. tuberculosis and
M. smegmatis-P1 (Fig. 3, lanes 3 and 4), but similar in size
to the band detected in 6-week M. tuberculosis culture fil-
trates (Fig. 3, lanes 5 and 7). Mycosin-1 without the
propeptide has a putative mass of ~39 kDa and these re-
sults therefore suggest that mycosin-1 is expressed and
may be processed during intracellular residence.
Subcellular localization of mycosin-1
Sequence analyses of mycosin-1 suggested that the pro-
tein is secreted and membrane anchored. Furthermore,
when expressed heterologously in M. smegmatis, my-
cosin-1 was located in the membrane / cell wall [3]. Sub-
fractionation of cell lysates into wall, membrane, and
intracellular fractions indicated that mycosin-1 was
present only in the cell wall and membrane fractions of M.
smegmatis-P1, as expected, and was also located in these
fractions in M. tuberculosis (Fig. 4). Consistent with this,
abundant staining for mycosin-1 was detected in the cell
envelope in both M. smegmatis-P1 (Fig. 5B) and in M. tu-
berculosis (Fig. 5D), by immunoelectronmicroscopy,
with minimal staining in the negative controls (Fig. 5A
and 5C).
Protease activity in mycobacterial fractions
Using 125I-fibrinogen as a substrate, we next examined
whether mycosin-1 possessed proteolytic activity. Assays
of whole cell lysates of E. coli or M. smegmatis expressing
mycosin-1, as well as purified GST-mycosin-1 fusion pro-
tein, revealed no protease activity (results not shown). The
recombinant GST-mycosin-1 fusion protein may have
been inactive because of incorrect folding of the fusion
protein or incorrect processing of the prepromycosin.
Propeptide removal is usually required for activation of
secreted bacterial proteases [4], but treatments of M. smeg-
matis-P1 lysates with acidic buffers or limited tryptic diges-
tion were unsuccessful (results not shown). The
Figure 3
Expression of mycosin-1 in mycobacteria in culture
and during infection of macrophages. Samples were
resolved by SDS-PAGE and analyzed by Western blotting
using anti-mycosin-1 antiserum. Lanes: 1, M. smegmatis; 2, M.
smegmatis transformed with p19Kpro; 3, M. smegmatis trans-
formed with p19K-P1; 4, M. tuberculosis clinical isolate GSH-
3052 cell lysate; 5, M. tuberculosis clinical isolate GSH-3052
culture filtrate after growth in Kirchner's broth for 6 weeks;
6, lysate of uninfected P388D1 macrophages; 7, lysate of M.
tuberculosis clinical isolate GSH-3052-infected P388D1 macro-
phages. Molecular weights (in kDa) are indicated on the left.
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Figure 4
Subcellular localization of mycosin-1 in M. smegmatis-
P1 and M. tuberculosis. Bacteria were isolated after three
weeks (M. tuberculosis) or two days (M. smegmatis) of growth
in culture. Bacterial cell lysates were subfractionated into cell
wall (w), cell membrane (m), and intracellular (i) fractions.
Fractions were resolved by SDS-PAGE and analyzed by
Western blotting using anti-mycosin-1 antiserum. Molecular
weights (in kDa) are indicated on the left.
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tion of mycosin-1 are unknown and evidently not present
in M. smegmatis. Moreover, the substrate specificity, opti-
mal pH and temperature, and requirement for cofactors
have not been determined for mycosin-1. M. tuberculosis
lysates were also inactive, but these were only tested after
heat-killing the pathogen at 80C for 45 min.
As lower molecular weight isoforms of mycosin-1 were
identified in culture and during infection of macrophages,
we next examined whether protease activity could be de-
tected in culture supernatants of M. tuberculosis. Although
variable from experiment to experiment, requiring 20-
fold concentration and extended (16–18 h) incubations
with substrate, protease activity could be detected in M.
tuberculosis culture filtrates after growth in Kirchner's me-
dium for 2 weeks, reaching a maximum after 4 weeks (re-
sults not shown). In contrast, M. bovis BCG culture filtrates
contained low levels of protease activity that were poorly
reproducible. Similarly, M. smegmatis culture filtrates con-
tained low or undetectable levels of protease activity, with
no differences between wild-type and transformed strains
(not shown).
To examine this proteolytic activity further, 125I-fibrino-
gen was incubated with M. tuberculosis GSH-3052 culture
filtrate in the presence of diverse, class-specific protease
inhibitors. This analysis revealed that the proteolytic activ-
ity was significantly inhibited by serine and cysteine pro-
tease inhibitors (Fig. 6), with strongest inhibition
Figure 5
Electron micrographs of M. smegmatis-P1 and M. tuberculosis following immunogold labeling with anti-
mycosin-1 antiserum. Bacterial pellets were first incubated with anti-mycosin-1 antiserum, fixed, cryosectioned, and labeled
with 5-nm gold particles. (A) M. smegmatis transformed with vector only (p19Kpro); (B) M. smegmatis-P1; (C) M. tuberculosis
incubated with pre-immune serum as primary antibody; and (D) M. tuberculosis incubated with anti-mycosin-1 antiserum.
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20%), ALLM (66  22%), and PMSF (66  30%). Some
subtilisins, including mycosin-1 (Fig. 2A), contain a
cysteine residue near the active site histidine, which
renders these enzymes susceptible to some cysteine pro-
tease inhibitors [5,6]. Moderate inhibition was also noted
with 3,4-dichloroisocoumarin (38  8%) and EDTA (33 
9%), whereas inhibition by other inhibitors was variable
and generally less than 20%. Proteolytic activity was en-
hanced 38% by the addition of 2.5 mM Ca2+ but was un-
affected by 0.1 mM Zn2+ (results not shown). The results
suggest that the predominant protease activity in M. tuber-
culosis culture filtrates comprise one or more serine and/or
cysteine proteases that are partially Ca2+ dependent. At-
tempts at purifying this activity failed (data not shown).
Conclusions
In conclusion, mycosin-1 is an extracellular protein that is
membrane- and cell wall-associated, and is shed into the
culture supernatant. The protein is expressed after infec-
tion of macrophages and may be subjected to proteolytic
processing intracellularly. Although proteolytically active
mycosin-1 could not be generated recombinantly, serine
protease activity was detected in M. tuberculosis culture fil-
trates. The function of the mycosins during intracellular
Figure 6
Degradation of 125I-fibrinogen by M. tuberculosis culture filtrates and inhibition by class-specific protease inhib-
itors. Culture filtrates were concentrated 20-fold and incubated with 125I-fibrinogen for 16 h. Class specific protease inhibitors
(defined in the text) were added to the protease assays, which were performed as described in the Methods. Extent of 125I-
fibrinogen degradation was quantified by measurement of TCA-soluble counts. Results are expressed as percent degradation
relative to control (no inhibitor) and are the means  standard deviations of four independent experiments.
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ther investigation.
Methods
Bacterial strains, plasmids, primers, and cloning
E. coli XL-1 Blue (Stratagene) was used as host strain for
transformations of the vectors pGEX-2T (Pharmacia),
p19Kpro (a gift from Koen De Smet, Imperial College
Medical School at St Mary's, London, UK), and pBlue-
scriptSK (pBS) (Stratagene). pGEX-2T is an E. coli expres-
sion vector for the expression of a heterologous protein
with an N-terminal GST fusion partner, and p19Kpro is a
mycobacterial expression vector derived from p16R1 with
a constitutive 19 kDa antigen promoter [3]. M. tuberculosis
clinical isolate GSH-3052 [7] and the laboratory strain
H37Rv were maintained on Lowenstein-Jensen slopes and
grown as liquid cultures in Kirchner's medium, at 37C
with shaking (200 rpm). M. smegmatis (mc2155) was
grown as described [3]. All DNA manipulations were car-
ried out using standard techniques [8]. Full-length mycP1
and mycP1 lacking the signal peptide-encoding sequence
(mycP1-) were amplified using 5'-ACA GGA TCC GTC
AAG TGG CCC AAG GTA GCA-3' (corresponding to nu-
cleotides -71 to -51) and 5'-CGT TCT AGA GGA TCC CCC
GCA TCG GCC ATC ACG-3' (corresponding to nucle-
otides 52–69) as the forward primers, respectively, and 5'-
AA AGA ATT CTG CAG TCA TCG GCG GCT CAG CG-3' as
the reverse primer. Amplification was performed with the
Expand™ High Fidelity PCR System (Roche) using approx-
imately 100 ng of M. tuberculosis cosmid Y15F10 DNA as
template (Genbank accession no. Z94121, obtained from
the Sanger Centre, UK). The mycP1 (containing ~70 bp
upstream of the putative start site to incorporate any puta-
tive translation signals) was cloned into p19Kpro (p19K-
P1), andmycP1- (lacking the signal peptide sequence) was
cloned in-frame with the glutathione S-transferase (GST)
gene in pGEX-2T (pGEX-P1). Electroporation of M. smeg-
matis was performed as described [9].
Antibody production and detection of mycosin-1 in M. 
smegmatis and M. tuberculosis
The GST-mycosin-1 fusion protein was expressed and pu-
rified essentially as described [10]. One hundred micro-
grams of purified GST-mycosin-1 in incomplete Freund's
adjuvant was injected subcutaneously into two female
New Zealand White rabbits. Three additional booster in-
jections were given at 3-week intervals. Approximately 10
ml of blood was taken from each rabbit at 1 and 2 weeks
after the last booster injection and used as anti-mycosin-1
antiserum. To enhance its specificity, the antiserum was
depleted of non-specific antibodies by consecutive pas-
sage over Sepharose 4B columns containing E. coli and M.
smegmatis cellular lysates.
To obtain mycobacterial cellular lysates, wild-type and
transformed M. smegmatis were grown in liquid broth,
cells were harvested by centrifugation, washed twice in
PBS, resuspended in 2% SDS, and then sonicated (W-385
sonicator, Heat Systems-Ultrasonics, Inc; output level 3;
80% duty cycle) on ice for 3 periods of 4 min each. After
extraction of protein at 60C for 2 h, the extract was cen-
trifuged at 12 000  g for 20 min to remove insoluble ma-
terial. SDS extraction of M. tuberculosis GSH-3052 proteins
was performed as above, except that prior to sonication
the bacteria were heat-killed at 80C for 45 min. In addi-
tion, culture filtrates from various stages of growth were
harvested, dialyzed against sterile water, and then lyophi-
lized.
Immunodetection of mycosin-1 during growth in macro-
phages
P388D1 macrophages were grown and maintained in
RPMI-1640 medium supplemented with 10% heat-inacti-
vated FBS and were infected with the M. tuberculosis clini-
cal strain GSH-3052 at a ratio of 50 bacilli/cell for 5 h at
37C. After washing in PBS, fresh RPMI-1640 medium
was added and the infected cells were incubated at 37 C
for 6 days. The cells were then washed with PBS to remove
any extracellular bacteria, detached in 5-mM EDTA, soni-
cated for three periods of 4 min on ice, and centrifuged at
100 000  g for 3 h. The pellet was resuspended in SDS
loading buffer, resolved by SDS-PAGE, and analyzed by
Western blotting, using anti-mycosin-1 antiserum (1:1
000) as the primary antibody.
Subcellular localization
To obtain subcellular fractions of M. smegmatis, bacteria
were isolated after two days of growth in culture, resus-
pended in PBS and sonicated, as described above. The
lysate was then centrifuged at 1 000  g for 30 min, to re-
move debris and intact bacteria. The supernatant was in-
cubated with DNAse I and RNAse at 4C overnight and
then centrifuged at 20 000  g to collect the cell wall frac-
tion (pellet). The supernatant was then centrifuged at 100
000  g for 3 h to isolate the cellular membranes (pellet)
and cytoplasm (supernatant), which was further concen-
trated 2–3 fold using 10 kDa Amicon spin columns. The
cell membrane and cell wall fractions were resuspended in
2% SDS and heated at 60C for 2 h, after which insoluble
components were again removed by centrifugation. Sub-
cellular fractionation of M. tuberculosis GSH-3052 pro-
teins was performed as above, except that cultures were
grown for 3 weeks and prior to sonication the bacteria
were heat-killed at 80C for 45 min.
For immunoelectronmicroscopy, whole bacteria were in-
cubated with anti-mycosin-1 or preimmune antiserum,
fixed in 2% paraformaldehyde / 0.05% gluteraldehyde in
0.1 M phosphate buffer (pH 7.4), embedded in 2% low-Page 7 of 8
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sage through a 50–100% sucrose gradient, and then cryo-
sectioned at -100 to -110C. Ultrathin sections were
placed onto formvar-coated nickel grids. Non-specific an-
tibody binding was blocked with 0.02 M glycine followed
by 1% BSA, and the grids were then incubated on goat
anti-rabbit IgG conjugated to 5 nm-diameter gold parti-
cles. After washing with 1% BSA and PBS, postfixing in 1%
gluteraldehyde and staining with uranyl acetate/methyl-
cellulose, the sections were viewed by transmission elec-
tron microscopy (Zeiss EM 109, 80 kV).
Assay of M. tuberculosis culture filtrates for protease activ-
ity and inhibition by class-specific protease inhibitors
Mycobacterial culture supernatants were harvested by cen-
trifugation, filtered (0.22-m filter), adjusted to 0.02% Na
azide, and concentrated 20-fold (Amicon, 10 kDa cut-
off). Mycobacterial culture filtrates, bacterial whole cell
lysates containing recombinant mycosin-1, and purified
GST-mycosin-1 fusion protein were assayed for proteolyt-
ic activity by incubation with 125I-labeled fibrinogen, pre-
pared as described [11]. Assays consisted of 200 l of
concentrated filtrate made up to a final volume of 500 l
in 75 mM Hepes, pH 7.3, containing 1.5–2.0  106 c.p.m.
125I-fibrinogen, and were incubated at 37C with rotation
for 16–18 h. Fibrinogen degradation was determined
quantitatively by trichloroacetic acid (TCA) precipitation
as described [11]. The inhibition of proteolytic activity of
M. tuberculosis culture filtrates by class-specific protease in-
hibitors was investigated by addition of each of the fol-
lowing inhibitors to the reaction: (A) Serine protease
specific inhibitors: 3, 4-DCI (3, 4-dichloroisocoumarin)
(1 mM), aprotinin (2 g/ml) and pefabloc (1 mM). (B)
Mixed serine and cysteine protease inhibitors: chymosta-
tin (0.2 mM), ALLN (N-acetyl-Leu-Leu-norleucinal or Cal-
pain Inhibitor I) (200 g/ml), ALLM (N-acetyl-Leu-Leu-
methional or Calpain Inhibitor II) (100 g/ml), PMSF
(phenylmethanesulfonyl fluoride) (1 mM), leupeptin
(0.4 mM), TPCK (L-1-chloro-3-[4-tosylamido]-4-phenyl-
2-butanone) (100 g/ml) and TLCK (L-1-chloro-3-[4-to-
sylamido]-7-amino-2-heptanone HCl) (100 g/ml). (C)
Cysteine protease specific inhibitor: E-64 (L-trans-epoxy-
succinyl-leucylamido-[4-guanidino]-butane) (0.05 mM).
(D) Aspartic protease specific inhibitor: pepstatin A (50
g/ml). (E) Metallo-protease inhibitors: EDTA (ethylene-
diaminotetraacetic acid) (10 mM), 1, 10-phenanthroline
(2 mg/ml) and phosphoramidon (0.09 mM).
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